EMEA-001006-PIP05-18-M01
Key facts
Invented name |
|
Active substance |
nintedanib
|
Therapeutic area |
|
Decision number |
P/0438/2021
|
PIP number |
EMEA-001006-PIP05-18-M01
|
Pharmaceutical form(s) |
Capsule, soft
|
Condition(s) / indication(s) |
Treatment of fibrosing Interstitial Lung Diseases (ILD)
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|